

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

RECEIVED  
SECRETARY OF I

04 AUG 16 P

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <b>GlaxoSmithKline</b>			
2. Address <input type="checkbox"/> Check if different than previously reported <b>1500 K Street, NW Suite 650</b>			
3. Principal Place of Business (if different from line 2) City: <b>Washington, DC</b> State/Zip (or Country) <b>20005</b>			
4. Contact Name <b>Janie A. Kinney</b>	Telephone <b>202-715-1000</b>	E-mail (optional)	5. Senate ID# <b>16293-12</b>
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID# <b>31461000</b>

**TYPE OF REPORT** 8. Year 2004 Midyear (January 1-June 30)  Year End (July 1-December 31)


9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇨ Termination Date \_\_\_\_\_ 11. No Lobbying Activity

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organization
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Expenses (nearest \$20,000)	\$10,000 or more <input checked="" type="checkbox"/> ⇨ <u>\$2,300,000</u> Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. <b>REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of
	<input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts used LDA definition
	<input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6013 of the Internal Revenue Code
	<input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 1631 of the Internal Revenue Code

Signature



Date

August 12, 2004

Printed Name and Title Sarah J. Walsh , Vice President, Federal Government Relations Tax and Pharmaceutical

LD-2 (REV. 6/98)

Page :

Registrant Name GlaxoSmithKline Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each** information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

H.R. 1561 To amend title 35, United States Code, with respect to patent fees, and for other purposes.

17. House(s) of congress and Federal agencies contacted

Check if None

U.S. House of Representatives

U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	
Philip Thevenet	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_



Registrant Name GlaxoSmithKline Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

S. 2493 Safe Import Act of 2004

S. 2328 Regarding importation of drugs

S. 2307 Regarding importation of drugs

H.R. 2427 Pharmaceutical Market Access Act of 2003

H.R. 847 To Amend the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription  
Canada

H.R. 4759 Australia Free Trade Agreement

17. House(s) of congress and Federal agencies contacted

Check if None

U. S. House of Representatives

U.S. Trade Representative

U. S. Senate

Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	
Philip Thevenet	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_

Date \_\_\_\_\_

Printed Name and Title

---

LD-2 (REV. 6/98)

Page 3

Registrant Name GlaxoSmithKline Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each** information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

S.650; HR 2857 Pediatric Research Equity Act of 2003  
 Maintaining U.S. commitment to the Montreal Protocol

17. House(s) of congress and Federal agencies contacted  
 U.S. House of Representatives  
 U.S. Senate  
 U.S. Department of Health and Human Services  
 U.S. Environmental Protection Agency  
 U.S. Department of State

Check if None  
 Office of Management and Budget  
 U.S. Food and Drug Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	
Philip Thevenet	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_





Registrant Name GlaxoSmithKline Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each** information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

S. 754 Improved Vaccine Affordability & Availability Act

S. 814 Bill to include Hepatitis A vaccines in the Vaccine Injury Compensation program under title XXI of Health Service Act

S. 2062 Class Action Fairness Act

H.R. 4766 Agriculture Appropriations 2005

17. House(s) of congress and Federal agencies contacted

Check if None

U.S. Department of Health and Human Services

U.S. House of Representatives

U.S. Senate

Office of National AIDS Policy

U.S. Trade Representative

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	
Philip Thevenet	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_

Date \_\_\_\_\_

Printed Name and Title

---

LD-2 (REV. 6/98)

Page

Registrant Name \_\_\_\_\_ Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each** information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

H.R. 4520 American Jobs Creation Act of 2004  
 S. 1637 Jumpstart Our Business Strength (JOBS) Act

17. House(s) of congress and Federal agencies contacted  Check if None

U.S. House of Representatives  
 U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	
Philip Thevenet	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

